A partnership agreement between Canada’s national drug development centre and a leading biotech is to focus on advancing game-changing cancer treatments.
Novelogics Biotechnology and the Centre for Drug Research and Development (CDRD) are joining forces to take forward the biotech’s novel antibody, which aligns with the immune system of a patient, making it safer and reducing potential side effects. The technology has already demonstrated – in early stage testing – that it could inhibit tumours linked to prostate cancer.
“We are excited to introduce our novel approach to treating cancer. Unlike other immunotherapies that function by modulating, inhibiting or blocking targets, our innovative drug works by intercepting. This is a new way of limiting the immune suppressive effects of the drug target, which offers a huge opportunity to make a difference in the fight against cancer. We look forward to a successful collaboration with CDRD and are thrilled to be working with their technical team of experts and state-of-the-art biologics facility,” explained Dr Wayne Cheney, Novelogics’ President and Chief Scientific Officer.
CDRD’s Head of Biologics Dr Ismael Samudio added: “This a great example of how CDRD is partnering with Canadian life sciences companies to advance promising discoveries and transform them into validated investments and improved health outcomes. By combining our expertise and specialized infrastructure, we aim to provide critical data to advance Novelogics’ technology and help bring new therapeutic treatments to market.”